Showing papers by "Wyne P. Lee published in 2001"
TL;DR: A critical role for BR3 in B cell ontogeny is underscored by data showing that the BR3 gene had been inactivated by a discrete, approximately 4.7 kb gene insertion event that disrupted the 3' end of theBR3 gene in A/WySnJ mice, which lack peripheral B cells.
433 citations
TL;DR: It is shown here that TACI-Fc blocks the activation of T cells in vitro and inhibits antigen-specific T cell activation and priming in vivo and in a mouse model for rheumatoid arthritis, treatment substantially inhibited inflammation, bone and cartilage destruction and disease development.
Abstract: Interactions of the tumor necrosis factor superfamily members B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) with their receptors-transmembrane activator and CAML interactor (TACI) and B cell maturation molecule (BCMA)-on B cells play an important role in the humoral immune response. Whereas BCMA is restricted to B cells, TACI is also expressed on activated T cells; we show here that TACI-Fc blocks the activation of T cells in vitro and inhibits antigen-specific T cell activation and priming in vivo. In a mouse model for rheumatoid arthritis (RA), an autoimmune disease that involves both B and T cell components, TACI-Fc treatment substantially inhibited inflammation, bone and cartilage destruction and disease development. Thus, BLyS and/or APRIL are important not only for B cell function but for T cell-mediated immune responses. Inhibition of these ligands might have therapeutic benefits for autoimmune diseases, such as RA, that involve both B and T cells.
214 citations
TL;DR: It is demonstrated that it is possible to customize the pharmacokinetic properties of a Fab' while retaining its antigen binding activity and all PEGylated Fab' molecules were as efficacious in reducing oedema as the original monoclonal antibody.
127 citations
TL;DR: The results suggest that CD62L is not required for activation of autoimmune CD4 T cells but is important for the final destructive function of effector cells in the CNS and support a novel mechanism wherebyCD62L expressed on effector Cells is important in mediating myelin damage.
70 citations
Patent•
12 Jan 2001
TL;DR: In this paper, the authors present methods and compositions useful in diagnosing and treating hepatic disorders, especially those characterized by inflammation, which can be employed to detect the presence of a disorder or to monitor the course of therapy used to treat the disorder.
Abstract: The present invention encompasses methods and compositions useful in diagnosing and treating hepatic disorders, especially those characterized by inflammation. The method comprises administration of an agent which prevents the interaction of ICAM with a ICAM binding partner or ligand. These compositions are useful in treating diseases or disorders involving LFA-I/ICAM blockade, as well as inhibiting a primary event in the inflammatory response such as blocking interactions between intercellular adhesion molecules and their ligands. Disorders treatable using the methods disclosed herein include infections, especially viral infections, iatrogenic disorders, cholestatic disorders, hereditary disorders, sarcoidosis, organ transplant, and the like. The diagnostic methods of the ivention can be employed to detect the presence of a disorder or to monitor the course of therapy used to treat the disorder.
Patent•
12 Jan 2001
TL;DR: Les methodes diagnostiques de cette invention peuvent permettre de detecter l'existence d'un trouble ou de surveiller le cours d'une therapie mise en oeuvre pour traiter ce trouble.
Abstract: La presente invention se rapporte a des methodes et a des compositions permettant de diagnostiquer et de traiter des troubles hepatiques, notamment ceux caracterises par une inflammation. Une telle methode consiste a administrer un agent qui previent l'interaction de la molecule d'adhesion intercellulaire ICAM-1 avec un partenaire de liaison ou un ligand de ICAM. Ces compositions s'averent utiles s'agissant de traiter des maladies ou des troubles impliquant un blocage de l'antigene associe a la fonction lymphocytaire (LFA-1) et/ou de la molecule ICAM, et s'agissant d'inhiber un evenement primaire de la reaction inflammatoire tel que le blocage des interactions entre les molecules d'adhesion cellulaires et leur ligands. Lesdites methodes permettent de traiter des troubles tels que des inflammations, et notamment les infections virales, des troubles iatrogenes, des troubles cholestatiques, des troubles hereditaires, la sarcoidose, les troubles lies a la transplantation d'organes et analogues. Les methodes diagnostiques de cette invention peuvent permettre de detecter l'existence d'un trouble ou de surveiller le cours d'une therapie mise en oeuvre pour traiter ce trouble.